High dose oral and intravenous rifampicin for improved survival from adult tuberculous meningitis: a phase II open-label randomised controlled trial (the RifT study)

Background: Tuberculous meningitis (TBM) has 44% (95%CI 35-52%) in-hospital mortality with standard therapy in Uganda. Rifampicin, the cornerstone of TB therapy, has 70% oral bioavailability and ~10-20% cerebrospinal fluid (CSF) penetration.  With current WHO-recommended TB treatment containing 8-12...

Descripción completa

Detalles Bibliográficos
Autores principales: Cresswell, Fiona V., Ssebambulidde, Kenneth, Grint, Daniel, te Brake, Lindsey, Musabire, Abdul, Atherton, Rachel R., Tugume, Lillian, Muzoora, Conrad, Lukande, Robert, Lamorde, Mohammed, Aarnoutse, Rob, Meya, David, Boulware, David R., Elliott, Alison M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113880/
https://www.ncbi.nlm.nih.gov/pubmed/30175245
http://dx.doi.org/10.12688/wellcomeopenres.14691.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113880/
https://www.ncbi.nlm.nih.gov/pubmed/30175245
http://dx.doi.org/10.12688/wellcomeopenres.14691.1

Ejemplares similares